Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.

A study of ruxolitinib cream in patients with lichen planus indicated that the topical JAK inhibitor is a promising potential ...

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two ...

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1Second approval of ZORYVE outside of the United ...

Results of a retrospective real-world study suggested no greater risk for major CV adverse events in patients treated with ...

Irish startup Luminate is developing a helmet that applies pressure across the surface of the scalp to reduce hair loss ...